samedan logo

 
 
spacer
home > ebr > autumn 2001 > personalised medicine draws nearer
PUBLICATIONS
European Biopharmaceutical Review

Personalised Medicine Draws Nearer

What's your broad perspective on the uptake of pharmacogenomics to-date as a drug development activity, and how significant do you think this is for the industry? First of all, we have long believed that pharmacogenomics is really the first application of the genomics revolution. In other words, the first key products that will come out of the whole genomics field will be in the form of molecular diagnostics, based on determining genetic variability in patient response to drugs. We believe the pharmaceutical industry is now moving rapidly to incorporate pharmacogenomics across drug development activities. For example, in most clinical trials, DNA is being isolated and stored, to be queried later against genetic markers identifying which patients are responding to drugs.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Taylor Crouch joined Variagenics, Inc. in April 1999 with a distinguished track record in pharmaceutical marketing and clinical development. Formerly Senior Vice President for worldwide marketing and strategic development at the multinational CRO, PAREXEL International Corporation, he also spent 10 years in the pharmaceutical and device industries in new product development marketing at Schering Plough International, Pfizer International and Johnson & Johnson's Critikon Division. A man with a clear vision for the future of pharmacogenomics in the development and commercialisation of new medicines, Crouch spoke with Helen Abbott, Editor of EBR, about this brave new world.
spacer
Taylor Crouch
spacer
spacer
spacer
Dr Helen Abbott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Merck Announces Collaboration with Agilent Technologies to Fill Industry Gap in Process Analytical Technologies for Downstream Processing

Darmstadt, Germany, June 14, 2022: Merck, a leading science and technology company, today announced that it has entered a collaboration with Agilent Technologies to advance Process Analytical Technologies (PAT). PAT, which is strongly encouraged by global regulatory authorities, is a key enabler for real-time release and Bioprocessing 4.0.
More info >>

White Papers

The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing

GE Healthcare Life Sciences

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These factors include: • The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model • Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint • The emergence of biosimilars and continued evolution of healthcare reform, which will increasingly pressure drug pricing and require greater cost discipline • Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures • Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement